Epirus grants Ranbaxy biosimilar marketing rights

Epirus Biopharmaceuticals Inc. (Boston, Mass.) granted Ranbaxy Laboratories Ltd. (NSE:RANBAXY; BSE:500359) rights to commercialize

Read the full 140 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE